Integrating Multimodal Evidence to Inform Trial Design & Dose Selection in Rare Disease Development

• Combining clinical, mechanistic, biomarker, and historical datasets to support modelinformed decision-making in rare disease programmes
• Designing development strategies when untreated baseline data is unavailable
• Building modelling frameworks that connect study design, analysis, and reporting to improve confidence in dose selection decisions

Speakers: